Trade Chromadex Corp - CDXC CFD

Add to favourite

3.7860

3.81%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0280

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Chromadex Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	3.936
Open*	3.976
1-Year Change*	178.55%
Day's Range*	3.766 - 3.976
52 wk Range	1.25-2.19
Average Volume (10 days)	38.94K
Average Volume (3 months)	1.39M
Market Cap	107.43M
P/E Ratio	-100.00K
Shares Outstanding	75.12M
Revenue	83.37M
EPS	-0.09
Dividend (Yield %)	N/A
Beta	1.86
Next Earnings Date	Mar 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 17, 2024	3.9360	-0.0200	-0.51%	3.9560	4.1560	3.8960
Apr 16, 2024	3.9360	0.1000	2.61%	3.8360	4.0460	3.7960
Apr 15, 2024	3.9060	0.0000	0.00%	3.9060	3.9560	3.7460
Apr 12, 2024	3.8260	-0.1200	-3.04%	3.9460	4.1560	3.5760
Apr 11, 2024	4.0660	0.1200	3.04%	3.9460	4.0760	3.8160
Apr 10, 2024	3.8960	-0.0800	-2.01%	3.9760	4.0160	3.7060
Apr 9, 2024	3.9660	-0.3000	-7.03%	4.2660	4.2860	3.8960
Apr 8, 2024	4.1960	0.1400	3.45%	4.0560	4.3460	4.0460
Apr 5, 2024	3.9760	-0.3200	-7.45%	4.2960	4.6160	3.8560
Apr 4, 2024	4.2860	0.3500	8.89%	3.9360	4.4560	3.8360
Apr 3, 2024	3.9360	0.3400	9.45%	3.5960	3.9360	3.5960
Apr 2, 2024	3.5860	-0.0300	-0.83%	3.6160	3.8860	3.5360
Apr 1, 2024	3.5960	0.2200	6.52%	3.3760	3.6160	3.1860
Mar 28, 2024	3.4760	-0.1200	-3.34%	3.5960	3.7360	3.1860
Mar 27, 2024	3.6460	-0.2100	-5.45%	3.8560	3.9260	3.5460
Mar 26, 2024	3.8360	0.0400	1.05%	3.7960	4.0060	3.4160
Mar 25, 2024	3.7660	0.2000	5.61%	3.5660	4.0460	3.5660
Mar 22, 2024	3.5360	0.3400	10.64%	3.1960	3.5760	2.9860
Mar 21, 2024	3.1960	0.2200	7.39%	2.9760	3.2260	2.9460
Mar 20, 2024	3.0460	0.4100	15.55%	2.6360	3.0560	2.3360

Chromadex Corp Events

Time (UTC)	Country	Event
Wednesday, May 8, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Chromadex Corp Earnings Release Q1 2024 Chromadex Corp Earnings Release Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 22:00	Country US	Event Chromadex Corp Annual Shareholders Meeting Chromadex Corp Annual Shareholders Meeting Forecast - Previous -
Wednesday, August 7, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Chromadex Corp Earnings Release Q2 2024 Chromadex Corp Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	72.05	67.449	59.257	46.291	31.557
Revenue	72.05	67.449	59.257	46.291	31.557
Cost of Revenue, Total	29.253	25.959	23.983	20.522	15.502
Gross Profit	42.797	41.49	35.274	25.769	16.055
Total Operating Expense	90.678	94.522	79.111	77.591	64.729
Selling/General/Admin. Expenses, Total	56.599	64.731	51.396	52.524	43.674
Research & Development	4.826	3.832	3.732	4.42	5.478
Unusual Expense (Income)
Other Operating Expenses, Total			0	0.125	0.075
Operating Income	-18.628	-27.073	-19.854	-31.3	-33.172
Interest Income (Expense), Net Non-Operating	0.003	-0.055	-0.071	-0.847	-0.079
Net Income Before Taxes	-16.54	-27.128	-19.925	-32.147	-33.316
Net Income After Taxes	-16.54	-27.128	-19.925	-32.147	-33.316
Net Income Before Extra. Items	-16.54	-27.128	-19.925	-32.147	-33.316
Total Extraordinary Items					0
Net Income	-16.54	-27.128	-19.925	-32.147	-33.316
Income Available to Common Excl. Extra. Items	-16.54	-27.128	-19.925	-32.147	-33.316
Income Available to Common Incl. Extra. Items	-16.54	-27.128	-19.925	-32.147	-33.316
Diluted Net Income	-16.54	-27.128	-19.925	-32.147	-33.316
Diluted Weighted Average Shares	69.729	67.185	61.067	57.056	55.006
Diluted EPS Excluding Extraordinary Items	-0.2372	-0.40378	-0.32628	-0.56343	-0.60568
Diluted Normalized EPS	-0.2372	-0.40378	-0.32628	-0.56343	-0.60568
Other, Net	2.085			0	-0.065

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	20.323	22.556	20.996	17.063	16.732
Revenue	20.323	22.556	20.996	17.063	16.732
Cost of Revenue, Total	7.967	9.038	8.98	6.856	6.69
Gross Profit	12.356	13.518	12.016	10.207	10.042
Total Operating Expense	22.639	24.524	22.44	20.128	23.119
Selling/General/Admin. Expenses, Total	13.307	14.293	12.181	12.048	15.184
Research & Development	1.365	1.193	1.279	1.224	1.245
Operating Income	-2.316	-1.968	-1.444	-3.065	-6.387
Interest Income (Expense), Net Non-Operating	0.125	0.066	0.026	-0.005	-0.01
Net Income Before Taxes	-2.191	-1.902	-1.418	-0.985	-6.397
Net Income After Taxes	-2.191	-1.902	-1.418	-0.985	-6.397
Net Income Before Extra. Items	-2.191	-1.902	-1.418	-0.985	-6.397
Net Income	-2.191	-1.902	-1.418	-0.985	-6.397
Income Available to Common Excl. Extra. Items	-2.191	-1.902	-1.418	-0.985	-6.397
Income Available to Common Incl. Extra. Items	-2.191	-1.902	-1.418	-0.985	-6.397
Diluted Net Income	-2.191	-1.902	-1.418	-0.985	-6.397
Diluted Weighted Average Shares	74.967	74.796	73.923	68.345	68.336
Diluted EPS Excluding Extraordinary Items	-0.02923	-0.02543	-0.01918	-0.01441	-0.09361
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.02923	-0.02543	-0.01918	-0.01441	-0.09361
Other, Net			0	2.085

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	46.567	48.905	32.219	33.518	36.534
Cash and Short Term Investments	20.241	28.219	16.697	18.812	22.616
Cash	20.241	28.219	16.697	18.812	22.616
Total Receivables, Net	8.482	5.226	2.694	2.175	5.092
Accounts Receivable - Trade, Net	5.382	3.126	1.794	1.375	4.415
Total Inventory	14.677	13.601	11.683	11.535	8.249
Prepaid Expenses	2.967	1.859	1.145	0.996	0.577
Total Assets	54.057	57.84	38.358	40.247	42.232
Property/Plant/Equipment, Total - Net	6.322	7.355	4.432	4.656	3.585
Property/Plant/Equipment, Total - Gross		11.899	8.086	7.446	5.636
Accumulated Depreciation, Total		-4.544	-3.654	-2.79	-2.051
Intangibles, Net	0.671	0.857	1.082	1.311	1.547
Long Term Investments
Other Long Term Assets, Total	0.497	0.723	0.625	0.762	0.566
Total Current Liabilities	17.869	17.613	16.476	15.063	14.44
Accounts Payable	9.679	10.423	9.445	9.626	9.548
Accrued Expenses	8.017	7.009	6.722	5.01	4.313
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.016	0.02	0.031	0.258	0.173
Other Current Liabilities, Total	0.157	0.161	0.278	0.169	0.406
Total Liabilities	25.385	26.113	21.934	19.802	15.054
Total Long Term Debt	0.022	0	0.02	0.018	0.137
Long Term Debt
Capital Lease Obligations	0.022	0	0.02	0.018	0.137
Other Liabilities, Total	7.494	8.5	5.438	4.721	0.477
Total Equity	28.672	31.727	16.424	20.445	27.178
Common Stock	0.074	0.068	0.062	0.06	0.055
Additional Paid-In Capital	214.094	200.614	158.19	142.285	116.876
Retained Earnings (Accumulated Deficit)	-185.493	-168.953	-141.825	-121.9	-89.753
Total Liabilities & Shareholders’ Equity	54.057	57.84	38.358	40.247	42.232
Total Common Shares Outstanding	74.567	68.126	61.881	59.562	55.089
Other Current Assets, Total	0.2
Note Receivable - Long Term					0
Other Equity, Total	-0.003	-0.002	-0.003

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	47.181	46.382	46.565	46.567	37.901
Cash and Short Term Investments	26.621	26.254	22.989	20.241	13.062
Cash	26.621	26.254	22.989	20.241	13.062
Total Receivables, Net	5.601	6.118	9.221	8.482	4.744
Accounts Receivable - Trade, Net	2.701	8.918	12.721	5.382	2.344
Total Inventory	12.624	11.973	11.908	14.677	15.636
Prepaid Expenses	2.183	1.885	2.295	2.967	4.259
Total Assets	53.483	53.171	53.768	54.057	45.665
Property/Plant/Equipment, Total - Net	5.296	5.68	6.041	6.322	6.505
Intangibles, Net	0.552	0.591	0.63	0.671	0.714
Other Long Term Assets, Total	0.454	0.518	0.532	0.497	0.545
Total Current Liabilities	19.444	19.061	18.423	17.869	16.727
Accounts Payable	9.198	10.031	8.951	9.679	9.119
Accrued Expenses	10.047	8.854	9.307	8.017	7.44
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.01	0.01	0.017	0.016	0.01
Other Current Liabilities, Total	0.189	0.166	0.148	0.157	0.158
Total Liabilities	26.175	26.021	25.751	25.385	24.642
Total Long Term Debt	0.014	0.017	0.02	0.022	0
Capital Lease Obligations	0.014	0.017	0.02	0.022
Other Liabilities, Total	6.717	6.943	7.308	7.494	7.915
Total Equity	27.308	27.15	28.017	28.672	21.023
Common Stock	0.075	0.075	0.074	0.074	0.068
Additional Paid-In Capital	217.808	216.691	215.367	214.094	205.027
Retained Earnings (Accumulated Deficit)	-190.574	-189.615	-187.424	-185.493	-184.075
Other Equity, Total	-0.001	-0.001	0	-0.003	0.003
Total Liabilities & Shareholders’ Equity	53.483	53.171	53.768	54.057	45.665
Total Common Shares Outstanding	74.91	74.856	74.666	74.567	68.169
Other Current Assets, Total	0.152	0.152	0.152	0.2	0.2

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-16.54	-27.128	-19.925	-32.147	-33.316
Cash From Operating Activities	-15.098	-24.163	-10.6	-20.439	-20.908
Cash From Operating Activities	0.869	0.89	0.871	0.762	0.607
Amortization	0.186	0.225	0.243	0.246	0.235
Non-Cash Items	6.705	6.86	5.252	10.902	6.375
Cash Interest Paid	0.001	0.001	0.013	0.033	0.041
Changes in Working Capital	-6.318	-5.01	2.959	-0.202	5.191
Cash From Investing Activities	-0.334	-0.409	-0.165	-0.249	-1.775
Capital Expenditures	-0.334	-0.409	-0.142	-0.753	-1.452
Other Investing Cash Flow Items, Total		0	-0.023	0.504	-0.323
Cash From Financing Activities	7.654	36.094	8.65	16.884	-0.09
Financing Cash Flow Items	-0.077	-0.11	-0.049	-0.678	-0.019
Issuance (Retirement) of Stock, Net	7.747	36.235	8.971	7.838	0.125
Issuance (Retirement) of Debt, Net	-0.016	-0.031	-0.272	9.724	-0.196
Net Change in Cash	-7.778	11.522	-2.115	-3.804	-22.773

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-1.902	-16.54	-15.122	-14.137	-7.74
Cash From Operating Activities	2.792	-15.098	-14.77	-11.03	-7.198
Cash From Operating Activities	0.228	0.869	0.648	0.413	0.201
Amortization	0.041	0.186	0.143	0.099	0.049
Non-Cash Items	1.781	6.705	5.14	3.713	2.215
Cash Interest Paid		0.001	0	0	0
Changes in Working Capital	2.644	-6.318	-5.579	-1.118	-1.923
Cash From Investing Activities	-0.091	-0.334	-0.162	-0.11	-0.025
Capital Expenditures	-0.091	-0.334	-0.162	-0.11	-0.025
Other Investing Cash Flow Items, Total
Cash From Financing Activities	-0.001	7.654	-0.025	-0.007	-0.003
Financing Cash Flow Items		-0.077	-0.015	0	0
Issuance (Retirement) of Stock, Net		7.747	0	0	0
Issuance (Retirement) of Debt, Net	-0.001	-0.016	-0.01	-0.007	-0.003
Net Change in Cash	2.7	-7.778	-14.957	-11.147	-7.226

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Chromadex Corp Company profile

About Chromadex Corp

ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.

Equity composition

Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.

Industry:

Biotechnology & Medical Research (NEC)

10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024